semaglutide is what Ozempic (semaglutide): Uses, Side Effects,

Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments

In a Phase 2 study, average weight loss in the first four weeks was about 25%, depending on the dose

Such is the extent of the shortage, that a recently published National Patient Safety Alert has advised against initiating new patients on GLP-1 agonists, especially for off-label indications, with market demand unlikely to be met until mid-2024

Focus on gradual, sustainable weight loss to keep these benefits long-term

In fact, most reports show a reduction in rates, but I would never argue with someone who says we need to learn more

Source: Jastreboff et al., NEJM 2022 (SURMOUNT-1)